Clinical and neurocognitive aspects of hallucinations in Alzheimer’s disease - Université de Lille Accéder directement au contenu
Article Dans Une Revue Neuroscience and Biobehavioral Reviews Année : 2017

Clinical and neurocognitive aspects of hallucinations in Alzheimer’s disease


Due to their prevalence, hallucinations are considered as one of the most frequent psychotic symptoms in Alzheimer’s disease (AD). These psychotic manifestations reduce patients’ well-being, increase the burden of caregivers, contribute to early institutionalization, and are related with the course of cognitive decline in AD. Considering their consequences, we provide a comprehensive account of the current state of knowledge about the prevalence and characteristics of hallucinations in AD. We propose a comprehensive and testable theoretical model about hallucinations in AD: the ALZHA (ALZheimer and HAllucinations) model. In this model, neurological, genetic, cognitive, affective, and iatrogenic factors associated with hallucinations in AD are highlighted. According to the ALZHA model, hallucinations in AD first involve trait markers (i.e., cognitive deficits, neurological deficits, genetic predisposition and/or sensory deficits) to which state markers that may trigger these experiences are added (e.g., psychological distress and/or iatrogenic factors). Finally, we provide recommendations for assessment and management of these psychotic manifestations in AD, with the aim to benefit patients, caregivers, and health professionals.

Dates et versions

hal-02391831 , version 1 (03-12-2019)



Mohamad El Haj, Jean Roche, Renaud Jardri, Dimitrios Kapogiannis, Karim Gallouj, et al.. Clinical and neurocognitive aspects of hallucinations in Alzheimer’s disease. Neuroscience and Biobehavioral Reviews, 2017, Neuroscience & Biobehavioral Reviews, 83, pp.713-720. ⟨10.1016/j.neubiorev.2017.02.021⟩. ⟨hal-02391831⟩
25 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More